ok continu chci improv
ep ahead consensu part due lower
expect vs better gross margin chca
revenu line chci exceed expect rx fell bit
short due suppli disrupt overal guidanc unchang
remain encourag prgo recent execut growth outlook still
appear challeng valuat look close full
consum busi post solid result gener lower due suppli
disrupt chca chci revenu exceed estim
respect although observ expect better perform due flu
rx pharma came lower given trend manag rais net sale
guidanc chci lower rx guidanc
revis larg offset henc overal revenu guidanc year
unchang gener busi rx impact suppli disrupt new
scopolamin patch launch transderm product expect
relaunch proair launch still anticip manag
estim rx net sale year book net net growth three
segment togeth remain rel constant low mid-singl digit rang
strong quarter chci due focus brand initi improv
product sourc addit rais revenu guidanc chci
manag also increas annual gross margin expect segment bp
improv attribut strateg focu right win
compani meaning strateg advantag market size ip uniqu oper
capabl well mix higher margin product moreov team also work
hard improv cog renew product sourc effort overarch goal
remain drive long-term chci margin expans high teen next year
store brand still gener place howev visibl major
over-the-counter categori switch temper medium-term outlook allergi ppi
cough switch larg play importantli still
appear clear major product categori rx over-the-counter switch opportun
near medium horizon allergi ppi cough-cold larg switch
end manag indic new line extens new dosag form
new channel e-commerce amazon could continu provid increment growth
key segment rx over-the-counter switch opportun like mostli singl
doubl longer term manag optimist regard macroenviron
given seemingli accommod fda view expans over-the-counter drug
part healthcar solut monograph modern act make
way congress pass senat monitor
dynam close key sustain long-term growth new major categori
without new visibl over-the-counter categori switch like viabl
pathway improv near term growth await new ceo capit
alloc strategi taken togeth like prgo posit leader
store brand consum healthcar increasingli think compani abil
acquisit end manag declin comment plan capit alloc
complet new ceo uwe rohrhoff strateg review sound like plan
unveil sometim fall meantim didnt stand complet still
regard compani finish quarter cash vs
repurchas anoth share note total debt larg unchang
compar
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
chart perrigo quarterli varianc analysi except per-shar data
page
pleas see import disclosur inform page report
changetot cost interest/oth incom ep fulli outstand fulli revenu changeconsum healthcar healthcar pharma
perrigo compani plc lead global healthcar supplier develop manufactur distribut over-the-count over-the-counter
prescript rx pharmaceut nutrit product activ pharmaceut ingredi api
david steinberg certifi view express research report accur reflect person view subject secur
subject compani also certifi part compens directli indirectli relat specif recommend
view express research report
edward chung certifi view express research report accur reflect person view subject secur
subject compani also certifi part compens directli indirectli relat specif recommend
view express research report
anthoni baldor certifi view express research report accur reflect person view subject secur
subject compani also certifi part compens directli indirectli relat specif recommend
view express research report
case jefferi employe analyst respons coverag financi instrument discuss report receiv
compens base part overal perform firm includ invest bank incom seek updat research
appropri variou regul may prevent us asid certain industri report publish period basi larg major
report publish irregular interv appropri analyst judgement
articl articl
explan jefferi rate
buy describ secur expect provid total return price appreci plu yield within period
hold describ secur expect provid total return price appreci plu yield plu minu within period
under-perform describ secur expect provid total return price appreci plu yield minu less within
expect total return price appreci plu yield buy rate secur averag secur price consist
within period compani typic volatil overal stock market hold rate secur averag
secur price consist expect total return price appreci plu yield plu minu within period
under-perform rate secur averag secur price consist expect total return price appreci plu yield minu
less within period
nr invest rate price target temporarili suspend suspens complianc applic regul and/
jefferi polici
cs coverag suspend jefferi suspend coverag compani
nc cover jefferi cover compani
restrict describ issuer conjunct jefferi engag certain transact compani polici applic secur
regul prohibit certain type commun includ invest recommend
monitor describ secur whose compani fundament financi monitor financi project opinion
invest merit compani provid
jefferi methodolog assign rate may includ follow market capit matur growth/valu volatil expect total
return next month price target base sever methodolog may includ restrict analys market
p/fcf premium discount /averag group ev/ebitda premium discount /averag group price-to-earnings sum part net asset valu dividend return
return equiti roe next month
jefferi franchis pick includ stock select among best stock idea equiti analyst month period stock select
base fundament analysi may take account factor analyst convict differenti analysi favor risk/reward
ratio invest theme jefferi analyst recommend jefferi franchis pick includ buy rate stock number
vari depend analyst recommend inclus stock ad new opportun aris remov reason
inclus chang stock met desir return longer rate buy and/or trigger stop loss stock day volatil
bottom quartil stock continu stop loss remaind stop franchis pick intend
repres recommend portfolio stock sector base may note believ pick fall within invest style
growth valu
page
pleas see import disclosur inform page report
risk may imped achiev price target
report prepar gener circul provid invest recommend specif individu investor
financi instrument discuss report may suitabl investor investor must make invest decis base
upon specif invest object financi situat util financi advisor deem necessari past perform
financi instrument recommend report taken indic guarante futur result price valu
incom financi instrument mention report rise well fall may affect chang econom financi
polit factor financi instrument denomin currenc investor home currenc chang exchang rate may
advers affect price valu incom deriv financi instrument describ report addit investor secur
adr whose valu affect currenc underli secur effect assum currenc risk
note box rate price target histori chart repres action past three year analyst initi
compani made chang rate price target compani discontinu coverag compani
import disclosur inform compani recommend report pleas visit websit http //javatar bluematrix com/sellside/
